KRAS and non-small cell lung carcinoma: Given the differences in available treatment toxicity profiles, and the limited treatment options for KRAS mutant NSCLC patients, erlotinib was considered an acceptable option in the selected geographies (32, 33) and the only approved third-line agent to use as a control arm at the time of initiation of the current study in selected geographies.